News
Form 8.3 - The Vanguard Group, Inc.: NortonLife Lock Inc.
Navidea Biopharmaceuticals Announces Third-Party Asset Valuation of Tc99m Tilmanocept for Indications in Rheumatoid Arthritis
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Pfizer to Acquire Arena Pharmaceuticals
Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical
DGAP-News: GEA Group Aktiengesellschaft: A Capital Market Information
DGAP-News: Deutsche Wohnen SE: CFO Philip Grosse joins Vonovia
DGAP-News: BP p.l.c.: Director/PDMR Shareholding
Nine in 10 Insurance Leaders in Europe Say Customer Experience is the Top Driver of Digital Transformation
Demand for improved customer experience is the top driver of digital transformation in Europe’s insurance industry, but with growing digitalization, insurers report increasing security
Northern Trust Launches New Climate Focus Reporting
Northern Trust (Nasdaq: NTRS) has further enhanced its suite of environmental, social and governance (ESG) investment analytics to deliver new climate risk reporting for global institutional
DGAP-News: Vonovia SE: Vonovia SE expands Management Board
Eurofins Technologies launches new Lateral Flow Reader RapidScan ST5-W as a single platform validated for multiple food and environmental rapid tests
Eurofins Technologies (Paris:ERF), a supplier of test kits and systems for laboratory analyses, announces the launch of its new RapidScan ST5-W lateral flow reader, specifically designed for field
Vifor Pharma comments on media speculation
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor is in discussions with CSL about a possible transaction. No decisions have been made yet and there is no time frame for this
Geneuro Receives CHF 6.7 Million (EUR 6.4 Million) in Funding From the Swiss Government for the Development of Temelimab Against Long-COVID
Regulatory News:
GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases, with final
Gensource Potash Announces Filing of Base Shelf Prospectus
Gensource Potash Corporation (“Gensource” or the “Company”) (TSXV: GSP, AIM: GSP) today announced that it has filed and obtained a final receipt (the “Receipt”) for a final short form base shelf
Elliptic Labs Signs Software License Agreement with New Smartphone Customer for Seven Smartphone Models
Elliptic Labs (EuroNext Growth: ELABS.OL), a global AI software company and the world leader in AI Virtual Smart SensorsTM, has signed a license agreement with a new Asia-based smartphone
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene
Sangamo Therapeutics Announces Updated Preliminary SAR445136 Phase 1/2 Proof-of-Concept Data Showing Tolerability and Sustained Effects in Sickle Cell Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary proof-of-concept clinical data from the Phase 1/2 PRECIZN-1 study of SAR445136, a zinc
DGAP-News: MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosis
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced
MaaT Pharma Presents Promising Clinical Data from 76 Patients with Acute Graft-vs-Host-Disease Treated with MaaT013 at 63rd ASH Annual Meeting
Regulatory News:
MaaT Pharma (EURONEXT: MAAT - the “Company“), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving
DGAP-News: MorphoSys and Incyte Announce Additional Real-World Evidence Results from RE-MIND2 Study of Tafasitamab (Monjuvi(R)) in Combination with Lenalidomide for the Treatment of r/r DLBCL
RRD Board Unanimously Determines that Chatham’s Unsolicited Proposal to Acquire RRD for $10.85 Per Share in Cash Constitutes a “Superior Proposal”
R.R. Donnelley & Sons Company (NYSE: RRD) (“RRD” or the “Company”) announced today that its Board of Directors (the “Board”) unanimously determined that an unsolicited proposal from Chatham Asset
Essex Property Trust Declares Quarterly Distributions
Essex Property Trust, Inc. (NYSE:ESS) announced today that its Board of Directors has declared a regular quarterly cash dividend of $2.09 per common share, payable January 14, 2022 to shareholders
SunMirror AG: Expanding the Team to Support the Execution of the Growth Strategy into Critical Raw Materials
SunMirror AG ("SunMirror", "the Company"; Vienna Stock Exchange: ROR1; Frankfurt Stock Exchange: ROR; ISIN CH0396131929) is pleased to announce experienced senior executives to join the SunMirror's
Puma Biotechnology Presents Updates from the SUMMIT Trial at the 2021 SABCS Annual Meeting
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, presented an update from its Phase II SUMMIT trial at the ongoing 2021 San Antonio Breast Cancer Symposium (SABCS) Annual